Casaevades el tema

Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment

Por um escritor misterioso
Last updated 09 abril 2025
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
A targeted nanoplatform co-delivery of pooled siRNA and
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Incorporation of drug efflux inhibitor and chemotherapeutic agent
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Overcoming P-Glycoprotein-Mediated Doxorubicin Resistance
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Medicinal chemistry strategies to discover P-glycoprotein
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Frontiers Multidrug Resistance in Cancer: Understanding
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Multifunctional nanoplatforms co-delivering combinatorial dual
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Cancers, Free Full-Text
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Increased drug efflux mediated by overexpression of P-glycoprotein
Recomendado para você
você pode gostar

© 2014-2025 startwindsor.com. All rights reserved.